HAMILTON, N.J., Jan. 26, 2017 /PRNewswire/ -- MedAvante, Inc., the leader in technology-based clinical trial services
Vallow's role will be to lead the expansion of MedAvante's VirgilŪ Investigative Study Platform into trials that rely on patient-reported outcomes (PRO) as key endpoint measures. The Virgil platform, which hosts all forms of electronic clinical outcome assessments (eCOA) including clinician-reported (ClinRO) and PRO instruments, is rapidly being adopted as pharmaceutical and biotech sponsors move to increasingly digitize clinical trials.
"Sue Vallow is a recognized expert in all aspects of patient-reported endpoints," said MedAvante president and co-founder Amy Ellis. "Her proven ability to develop patient engagement strategies that not only capture treatment benefits but also demonstrate the value of new medicines to regulatory agencies, providers and payers will be immensely beneficial for drug developers planning clinical trials across a spectrum of therapeutic areas."
At GSK, Vallow managed the team responsible for overseeing patient outcomes strategies across the R&D portfolio, as well as all clinical trials that used PRO measures and electronic implementation of those instruments (ePRO). Prior to GSK, she worked at Janssen in a leading role for PRO implementation in neuroscience.
An active voice in the pharmaceutical industry, Vallow served as co-chair of the ePRO subcommittee of the Critical-Path Institute's Patient Reported Outcomes Consortium, a member of PhRMA's PRO working group, and a leader of the TransCelerate Patient Experience & Technology (PE&T) initiative. She is a co-author of more than 20 peer-reviewed papers and more than 70 research posters and presentations.
"Sue brings an impressive array of strategic skills and clinical know-how, attributes that have earned her extensive respect in the industry," said Ellis. "She will be tremendously important to our efforts to expand the Virgil platform, especially our smartphone-based app that integrates seamlessly with the Virgil tablet-based software used by clinicians at more than 900 sites worldwide."
MedAvante is the global clinical data services company dedicated to maximizing signal detection in clinical trials. Founded in 2002, MedAvante pioneered Central Ratings, a groundbreaking clinical trial methodology. This heritage of clinical expertise, coupled with technical innovation and operational skills, enabled MedAvante to develop the electronic source (eSource) platform, Virgil, the first such technology to replace costly and error-prone paper rating scales with real-time digital collection and cloud management of source data. Designed by clinicians for clinicians, Virgil offers built-in clinical guidance to ensure accurate, standardized assessments. MedAvante helps brings better drug therapies to market through smarter, faster clinical trials. Based in Hamilton, NJ with operations teams in the US, Germany, Russia and Japan, MedAvante delivers services for clinical trials in more than 40 countries worldwide. For more information, please visit www.medavante.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/medavante-names-leader-for-patient-focused-esolutions-300397506.html
SOURCE MedAvante, Inc.
Subscribe to our Free Newsletters!
Blood groups are of four important groups determined by the presence or absence of specific ...
Spermatocele is a condition in which there is a blockage in the epididymal duct, resulting in semen ...
Be a blood donor and save lives for your donated blood is separated into blood products or just ...View All